Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedincellMDCLF +393.00%77 EV-to-Revenue is 46.79 as of Jul. 14, 2026, which is 21% above its 10-year median of 38.73. GuruFocus rates MDCLF with a GF Score™ of 77/100 and a GF Value™ of $27.51. The stock has 5 warning signs investors should review. Among 953 Biotechnology companies, Medincell ranks worse than 77.86% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Medincell's enterprise value is $1,065.29 Mil.
Medincell's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $22.77 Mil. Therefore, Medincell's EV-to-Revenue for today is 46.79.
The historical rank and industry rank for Medincell's EV-to-Revenue or its related term are showing as below:
MDCLF'
s EV-to-Revenue Range Over the Past 10 Years
Min: 14.38 Med: 38.73 Max: 114
Current: 48.33
During the past 11 years, the highest EV-to-Revenue of Medincell was 114.00. The lowest was 14.38. And the median was 38.73.
MDCLF's EV-to-Revenue is ranked worse than 77.86% of 953
companies
in the Biotechnology industry
Industry Median: 8.57
vs MDCLF: 48.33
As of today (2026-07-14), Medincell's stock price is $34.39.
Medincell's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.67. Therefore, Medincell's PS Ratio for today is 51.56.
Medincell's share price for today is $34.39.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Mar. 2026 was $0.67.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medincell EV-to-Revenue Related Terms
Medincell EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Medincell's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDCLF vs VRTX, REGN, ALNY: EV-to-Revenue Comparison
For the Biotechnology subindustry, Medincell's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medincell EV-to-Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medincell's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Medincell's EV-to-Revenue falls into.
Medincell's current Enterprise Value is $1,065.29 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medincell's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $22.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medincell (MDCLF) has a EV-to-Revenue of 46.79 as of Jul. 14, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Medincell and its competitors. This is 21% above median its historical median of 38.73. Over the past decade, Medincell's EV-to-Revenue has ranged from 14.38 to 114.00. According to the industry distribution chart, Medincell ranks #742 out of 953 companies in the Biotechnology industry, placing it in the top 77.9%.
Is Medincell's EV-to-Revenue too high?
Medincell's current EV-to-Revenue of 46.79 is 21% above median its 10-year median of 38.73. Over the past 10 years, this metric has ranged from a low of 14.38 to a high of 114.00. The Biotechnology industry median EV-to-Revenue is 8.57. Medincell's value of 46.79 is 446% above this industry median. Based on the distribution chart, Medincell ranks #742 out of 953 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's EV-to-Revenue compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medincell ranks #742 out of 953 companies for EV-to-Revenue. This places Medincell in the lower half of its industry. The industry median EV-to-Revenue is 8.57. Medincell's value of 46.79 is 446% above this benchmark. Historically, Medincell's own EV-to-Revenue has ranged from 14.38 to 114.00 over the past decade. While the company's 10-year median is 38.73 vs. the industry median of 8.57, Medincell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Biotechnology company?
The median EV-to-Revenue among Biotechnology companies is 8.57, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medincell's current EV-to-Revenue of 46.79 is 446% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Medincell and its competitors. For the Biotechnology industry, the median EV-to-Revenue is 8.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medincell's current EV-to-Revenue is 46.79, which is 21% above median its own 10-year median of 38.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current EV-to-Revenue of 46.79. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current EV-to-Revenue is 46.79, which is 21% above median its 10-year median of 38.73 and 446% above the Biotechnology industry median of 8.57. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Medincell (MDCLF), the current EV-to-Revenue is 46.79 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (MDCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.
Key valuation signals for MDCLF:
EV-to-Revenue: 46.79 (21% above median its 10-year median of 38.73)
GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
Industry Position: 446% above the Biotechnology median (#742 of 953)
No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score
Get the complete analysis for MDCLF
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCLF has been successfully added to your 
